The cost of caution: rethinking exercise in hypertrophic cardiomyopathy. [PDF]
Proc (Bayl Univ Med Cent)Saeyeldin A.
europepmc +1 more source
Efficacy and safety of mavacamten in non-obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized trials. [PDF]
Int J Cardiol Heart VascAbdullah M +11 more
europepmc +1 more source
Cryo-EM reveals how cardiomyopathy therapeutic drugs modulate the myosin motors of the heart. [PDF]
Sci AdvSomavarapu AK +4 more
europepmc +1 more source
Force-Induced Ankle Opening Reveals Mechanical Stabilization of the Ankle of Human β-Cardiac Myosin. [PDF]
ACS NanoDeopa SPS +9 more
europepmc +1 more source
Human Leukocyte Antigen Determinants in Myocarditis and Dilated Cardiomyopathy. [PDF]
Curr Heart Fail RepGoli N, Wilcox J, Barnard J, Tang WHW.
europepmc +1 more source
One- and two-year structural changes of mavacamten therapy in hypertrophic obstructive cardiomyopathy: a case report with serial comprehensive CMR demonstrating continuous reverse remodelling. [PDF]
Eur Heart J Case RepSeuthe K +4 more
europepmc +1 more source
Research progress on pathogenic genes of dilated cardiomyopathy. [PDF]
iScienceZhang X +5 more
europepmc +1 more source
Non-muscle myosin II is a promising therapeutic target. [PDF]
Trends Pharmacol SciMiller CA +2 more
europepmc +1 more source
Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy. [PDF]
ESC Heart FailUsai P +11 more
europepmc +1 more source
Small Molecules to Treat Cardiovascular Disease: Cardiac Myosin Inhibitors
Cardiovascular Innovations and Applicationsopenaire +1 more source